PMS2
Showing 1 - 25 of 460
Lynch Syndrome, Lynch Syndrome I, Lynch Syndrome II Trial in Milan (Video capsule endoscopy)
Recruiting
- Lynch Syndrome
- +7 more
- Video capsule endoscopy
-
Milan, Lombardia, ItalySan Raffaele Scientific Institute, Gastroenterology and Gastroin
Jan 27, 2023
Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS)
Recruiting
- SARS-CoV-2 Infection
-
Aichi, Japan
- +2 more
Jan 17, 2023
BARD1 Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation Trial in Houston, Seattle (Educational Intervention, Genetic
Recruiting
- BARD1 Gene Mutation
- +14 more
- Educational Intervention
- +3 more
-
Houston, Texas
- +1 more
Jun 14, 2022
LYNPARZA Breast Cancer in Adjuvant Setting Japan Post-Marketing
Not yet recruiting
- Breast Cancer
- (no location specified)
Jan 9, 2023
(PMS) for the Long-term Safety of VAXZEVRIA
Active, not recruiting
- Prevention of Infectious Disease Caused by SARS-CoV-2
-
Chiba, Japan
- +5 more
Nov 24, 2022
An Intervention to Increase Genetic Testing in Families Who May
Recruiting
- BRCA1 Mutation
- +21 more
- Intervention Arm At-risk Relative/ARR Contacts
- +5 more
-
Basking Ridge, New Jersey
- +7 more
Nov 22, 2022
(PMS) for Underlying Disease at High-risk for Worsening COVID-19
Recruiting
- Prevention of Infectious Disease Caused by SARS-CoV-2
-
Akita, Japan
- +9 more
Feb 1, 2023
(PMS) in Korean Patients With Type 2 Diabetes Mellitus
Recruiting
- Diabetes Mellitus, Type 2
-
Cheonan-si, Cheonan-si, Chungcheongnam-do, Korea, Republic of
- +2 more
Jul 26, 2022
Cascade Testing in Families With Newly Diagnosed Hereditary
Recruiting
- BRCA-Mutated Ovarian Carcinoma
- +7 more
- CASCADE genetic screening
-
New York, New YorkNYU Langone Health
Apr 30, 2021
End Stage Renal Disease, Restless Legs Syndrome Trial in Halifax, Hamilton, Ottawa (Gabapentin, Ropinirole, Placebo Gabapentin)
Completed
- End Stage Renal Disease
- Restless Legs Syndrome
- Gabapentin
- +3 more
-
Halifax, Nova Scotia, Canada
- +2 more
Sep 19, 2022
(PMS) Protocol of REKOVELLE Pre-Filled Pen (Follitropin Delta)
Recruiting
- Infertility, Female
- Other: Non intervention
-
Busan, Korea, Republic of
- +7 more
May 17, 2022
Deleterious BARD1 Gene Mutation, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation Trial in United States
Active, not recruiting
- Deleterious BARD1 Gene Mutation
- +13 more
- Laboratory Biomarker Analysis
- +4 more
-
Chicago, Illinois
- +8 more
Feb 25, 2022
PMS, Hot Flashes Trial in Changhua (I capsule, II RDC 0.3mg capsule, III RDC 0.6mg capsule)
Completed
- PMS
- Hot Flashes
- I placebo capsule
- +2 more
-
Changhua, TaiwanChanghua Christian Hospital
Feb 11, 2022
Atrial Fibrillation, Stroke Trial in Hamilton (Colchicine, Placebo)
Completed
- Atrial Fibrillation
- Stroke
- Colchicine
- Placebo
-
Hamilton, Ontario, CanadaHamilton General Hospital
Feb 19, 2021
SAPIEN 3 Ultra EU PMS
Recruiting
- Aortic Stenosis
- Aortic Valve Stenosis
- Transcatheter Aortic Valve Implantation (TAVI)
-
Graz, Austria
- +27 more
Dec 7, 2022
Implantation of HeartMate 3 in Heart Failure Using Surgical
Completed
- Advanced Refractory Left Ventricular Heart Failure
- HeartMate 3 Left Ventricular Assist System (HM3 LVAS)
-
Little Rock, Arkansas
- +31 more
Jan 31, 2023
XIENCE Xpedition Everolimus-Eluting Coronary Stent Japan Post
Completed
- Ischemic Heart Disease
- +3 more
- XIENCE Xpedition 2.25 mm stent
-
Hyogo, Japan
- +10 more
Apr 20, 2021
Symbenda Post-Marketing Surveillance (PMS)
Completed
- Lymphoma, Non-Hodgkin
- +2 more
-
Busan, Korea, Republic of
- +8 more
Jan 25, 2021
Reduction of Intestinal Inflammatory Activity Trial in Hamburg (Gluten-free diet)
Recruiting
- Reduction of Intestinal Inflammatory Activity
- Gluten-free diet
-
Hamburg, GermanyUniversitätsklinikum Hamburg Eppendorf
May 10, 2023
Metastatic Carcinoma in the Liver, MLH1 Gene Mutation, MSH6 Gene Mutation Trial in Duarte (Durvalumab, Laboratory Biomarker
Completed
- Metastatic Carcinoma in the Liver
- +6 more
- Durvalumab
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Dec 23, 2019
VeDOlizumab PERsistence in IBD Patients After Switching From
Recruiting
- Inflammatory Bowel Diseases
- Subcutaneous vedolizumab
-
Grenoble, Auvergne-Rhone-Alpes, FranceThomas Chateau
Aug 2, 2022
A 24-month Real Life PErsistence Efficacy and Safety Study in
Recruiting
- Inflammatory Bowel Diseases
- Subcutaneous infliximab CT-P13 Remsima®SC
-
Grenoble, FranceNicolas Mathieu
Aug 2, 2022
Precision-Based Genomics in Prostate Cancer
Recruiting
- Prostate Cancer
-
La Jolla, California
- +4 more
Jul 28, 2022
Germline Mutations Associated With Hereditary Pancreatic Cancer
Recruiting
- Pancreatic Cancer
- Pancreatic Adenocarcinoma
- Invitae Multi-Cancer Panel ®
-
Mexico City, MexicoInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubi
Mar 22, 2022